Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells

Epithelial to mesenchymal transition (EMT) induces cell plasticity and promotes metastasis. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) and the pleiotropic cytokine interleukin 6 (IL-6) have both been implicated in tumor cell metastasis and EMT, but via distinct pathways. Here, we show that direct interplay between YB-1 and IL-6 regulates breast cancer metastasis. Overexpression of YB-1 in breast cancer cell lines induced IL-6 production while stimulation with IL-6 increased YB-1 expression and YB-1 phosphorylation. Either approach was sufficient to induce EMT features, including increased cell migration and invasion. Silencing of YB-1 partially reverted the EMT and blocked the effect of IL-6 while inhibition of IL-6 signaling blocked the phenotype induced by YB-1 overexpression, demonstrating a clear YB-1/IL-6 interdependence. Our findings describe a novel signaling network in which YB-1 regulates IL-6, and vice versa, creating a positive feed-forward loop driving EMT-like metastatic features during breast cancer progression. Identification of signaling partners or pathways underlying this co-dependence may uncover novel therapeutic opportunities.

[1]  R. Simpson,et al.  YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment , 2015, Oncotarget.

[2]  Jun Cui,et al.  YB-1 overexpression promotes a TGF-β1-induced epithelial-mesenchymal transition via Akt activation. , 2015, Biochemical and biophysical research communications.

[3]  C. Galet,et al.  YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence , 2015, Oncotarget.

[4]  Sujin Kang,et al.  Differential Control of Interleukin-6 mRNA Levels by Cellular Distribution of YB-1 , 2014, PloS one.

[5]  Jia‐yuan Peng,et al.  Knockdown of Y‑box‑binding protein‑1 inhibits the malignant progression of HT‑29 colorectal adenocarcinoma cells by reversing epithelial‑mesenchymal transition. , 2014, Molecular medicine reports.

[6]  G. Mills,et al.  YB‐1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal‐Like Breast Cancer , 2014, Stem cells.

[7]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[8]  I. Giannopoulou,et al.  Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  S. Chiu,et al.  YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin , 2014, Oncotarget.

[10]  J. Bromberg,et al.  The IL-6 feed-forward loop: a driver of tumorigenesis. , 2014, Seminars in immunology.

[11]  L. Su,et al.  Loss of CDH1 up‐regulates epidermal growth factor receptor via phosphorylation of YBX1 in non‐small cell lung cancer cells , 2013, FEBS letters.

[12]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[13]  R. Mantovani,et al.  Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y? , 2013, Cell Death and Differentiation.

[14]  K. Kuroiwa,et al.  YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α , 2013, Cancer Immunology, Immunotherapy.

[15]  S. Ramón y. Cajal,et al.  Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines , 2013, PloS one.

[16]  M. Krzywinski,et al.  MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition , 2012, Oncogene.

[17]  C. Tognon,et al.  On translational regulation and EMT. , 2012, Seminars in cancer biology.

[18]  S. Brandt,et al.  Cold shock Y-box protein-1 participates in signaling circuits with auto-regulatory activities. , 2012, European journal of cell biology.

[19]  Y. Sasaguri,et al.  Strong YB‐1 expression is associated with liver metastasis progression and predicts shorter disease‐free survival in advanced gastric cancer , 2012, Journal of surgical oncology.

[20]  D. Dinh,et al.  Role of MMP-2 in the Regulation of IL-6/Stat3 Survival Signaling via Interaction With α5β1 Integrin in glioma , 2012, Oncogene.

[21]  S. Ramón y. Cajal,et al.  The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model. , 2011, International journal of oncology.

[22]  J. Datta,et al.  IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial–Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway , 2011, Molecular Cancer Research.

[23]  S. Dave,et al.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.

[24]  S. Dunn,et al.  YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention , 2011, Oncotarget.

[25]  Johan Staaf,et al.  GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  R. Karunanithi,et al.  Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients , 2011, World journal of surgical oncology.

[28]  Chih-Hsin Tang,et al.  IL-6 Increases MMP-13 Expression and Motility in Human Chondrosarcoma Cells* , 2011, The Journal of Biological Chemistry.

[29]  Robert H. Jenkins,et al.  A Conserved Stem Loop Motif in the 5′Untranslated Region Regulates Transforming Growth Factor-β1 Translation , 2010, PloS one.

[30]  A. Pollock,et al.  YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. , 2010, Biochemical and biophysical research communications.

[31]  Alan Wells,et al.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition , 2010, Molecular Cancer.

[32]  C. Eaves,et al.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. , 2010, Cancer research.

[33]  E. Dahl,et al.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer , 2009, BMC Cancer.

[34]  P. Sehgal.  Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial to mesenchymal transformation (EMT) in breast cancer cells , 2009, Oncogene.

[35]  C. Asselin,et al.  Constitutively active MEK1 is sufficient to induce epithelial‐to‐mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis , 2009, International journal of cancer.

[36]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[37]  T. Triche,et al.  Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.

[38]  J. Brugge,et al.  YB-1 translational control of epithelial-mesenchyme transition. , 2009, Cancer cell.

[39]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[40]  C. Riley,et al.  Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas , 2008, British Journal of Cancer.

[41]  Yong-Yeon Cho,et al.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells , 2008, Breast Cancer Research.

[42]  C. Eaves,et al.  Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. , 2008, Cancer research.

[43]  Samuel Leung,et al.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes , 2008, Breast Cancer Research.

[44]  K. Kohno,et al.  Mdr1 Resistance Gene Yb-1-mediated Activation of the Multidrug Ap-endonuclease (ape1/ref-1) in Regulatory Role of Human Supplemental Material , 2008 .

[45]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[46]  M. Karin,et al.  Autocrine IL-6 signaling: a key event in tumorigenesis? , 2008, Cancer cell.

[47]  F. Portillo,et al.  SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. , 2007, Cancer research.

[48]  J. Brugge,et al.  IL-6 involvement in epithelial cancers. , 2007, The Journal of clinical investigation.

[49]  A. Axel,et al.  Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer , 2007 .

[50]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[51]  R. Kalluri,et al.  Mechanisms of metastasis: Epithelial‐to‐mesenchymal transition and contribution of tumor microenvironment , 2007, Journal of cellular biochemistry.

[52]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[53]  Heike Knüpfer,et al.  Significance of interleukin-6 (IL-6) in breast cancer (review) , 2007, Breast Cancer Research and Treatment.

[54]  D. Laune,et al.  Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.

[55]  L. Kühn,et al.  Destabilization of Interleukin-6 mRNA Requires a Putative RNA Stem-Loop Structure, an AU-Rich Element, and the RNA-Binding Protein AUF1 , 2006, Molecular and Cellular Biology.

[56]  Poul H. B. Sorensen,et al.  Y-box Binding Protein 1: Providing a New Angle on Translational Regulation , 2006, Cell cycle.

[57]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[58]  Kuo-Bin Li,et al.  Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. , 2005, International journal of oncology.

[59]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[60]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[61]  D. Lovett,et al.  Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). , 2002, The Biochemical journal.

[62]  S. Esnault,et al.  Y Box-Binding Factor Promotes Eosinophil Survival by Stabilizing Granulocyte-Macrophage Colony-Stimulating Factor mRNA1 , 2001, The Journal of Immunology.

[63]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[64]  M. Mann,et al.  Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. , 2000, Genes & development.

[65]  A Cestelli,et al.  RNA-protein interactions in the control of stability and localization of messenger RNA (review). , 2000, International journal of molecular medicine.

[66]  T. Garcia,et al.  Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. , 1997, Nucleic acids research.

[67]  T. Yoneda,et al.  E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. , 1996, Cancer research.

[68]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[69]  C. Print,et al.  YB-1: oncoprotein, prognostic marker and therapeutic target? , 2013, The Biochemical journal.

[70]  A. Axel,et al.  Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.